Treatment of refractory solar urticaria: could dupilumab fill the current gap?

J Dtsch Dermatol Ges. 2023 Jun;21(6):652-653. doi: 10.1111/ddg.15025. Epub 2023 May 8.

Authors

Francisco José Navarro-Triviño¹, Alvaro Prados-Carmona², José Aguilera³, Maria Victoria de Gálvez³, Ricardo Ruiz-Villaverde²

Affiliations

¹ Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
² Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
³ Dermatological Photobiology and Cutaneous Oncology Unit, Department of Dermatology and Medicine, University of Malaga, Malaga, Spain.

PMID: 37154304
DOI: 10.1111/ddg.15025

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Urticaria* / drug therapy
Urticaria* / etiology
Urticaria, Solar*

Substances

dupilumab
Antibodies, Monoclonal, Humanized